2023Unpublished venueOpen access

POS1287 KL6 AND IL-18 LEVELS ARE NEGATIVELY CORRELATED WITH RESPIRATORY FUNCTION TESTS AND ILD EXTENT ASSESSED ON HRCT IN PATIENTS WITH SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE (SSC-ILD)

C. Sieiro Santos, Sara Calleja Antolín, J. de la Calle Lorenzo, Carmen López Garay, Clara Moriano, Elena Bollo de Miguel, Elvira Díez Álvarez

Open full text 0 citations

Abstract

Background Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with systemic sclerosis (SSc). Serum biomarkers have been suggested as indicators for pulmonary damage with clinical value in the diagnosis and prognosis of SSc-ILD. Objectives To investigate the role of serum biomarkers (Krebs von den Lungen-6 KL-6, IL-18 and IL-18BP) as potential biomarkers reflecting the severity of SSc-ILD as assessed through high-resolution computed tomography (HRCT) and pulmonary function tests (PFT), including forced vital capacity (%FVC) and diffusing capacity of the lung for carbon monoxide (%DLCO). Methods A cross-sectional study including patients with SSc fulfilling the 2013 ACR/EULAR criteria was performed. Patients were classified according to disease duration and pulmonary involvement (presence of ILD). All SSc patients underwent chest HRCT scans and pulmonary function test at baseline. Serum concentration of KL-6, IL8 and IL18BP were determined using sandwich ELISA technique (solid phase sandwich Enzyme Linked-Immunosorbent Assay), with kits from MyBiosource for KL-6 and from Invitrogen for IL18 and IL18BP. A semiquantitative grade of ILD extent was evaluated through HRCT scan (grade 1, 0–20%; grade 2, >20%). Extensive lung disease was defined as >20% of lung involvement on HRCT, and FVC <70% predicted and limited lung involvement as ≤20% of ILD involvement on HRCT, and an FVC ≥70% predicted. Results 74 patients were included, 27% were male. The mean age at diagnosis was 57.5±15 years. The mean time since diagnosis was 7.67±8 years. 28 patients had ILD (38%). 64 % of patients had <20% of ILD extent classified through HRCT scan. SSc-ILD patients had elevated serum KL-6 and IL-18 levels compared to patients without ILD (p=0.003 and p=0.04), and those findings were preserved after adjusting for age and sex (Table 1). Mean erythrocyte sedimentation rate (ESR) was higher in patients with SSc-ILD. A negative correlation between KL-6 levels and %FVC (β=-0.25, p 0.037) and %DLCO (β=-0.28, p 0.02) and between IL-18 levels and %FVC (β=-0.20, p 0.03) and %DLCO (β=-0.14, p 0.04) were found. Linear regression models representing correlation between KL-6 and PFT are represented in the scatter plot in Figure 1. Serum KL-6 and IL-18 levels successfully differentiated grades 1 and 2 (p = 0.028 and p=0.021). Semiquantitative grades of ILD on the HRCT scan were significantly proportional to the KL-6 (p 0.01) and IL-18 (p=0.03). A positive correlation between extensive lung disease and KL-6 (β=0.61, p 0.007) but not with IL-18 was found. Conclusion Serum KL-6 levels and IL-18 were increased in patients with SSc-ILD and showed a positive correlation with ILD severity as measured using a semiquantitative HRCT grading scale and a negative correlation with PFT parameters. KL-6 is positively correlated with extensive lung disease. Serum KL-6 and IL-18 could be a clinically useful biomarker in screening and evaluating SSc-ILD. Reference [1]Lee, J.S., Lee, E.Y., Ha, YJ. et al. Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease. Arthritis Res Ther 21, 58 (2019). https://doi.org/10.1186/s13075-019-1835-9 Acknowledgements: NIL. Disclosure of Interests None Declared.

Open-access reader

About this research paper

What this paper is about

Background Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with systemic sclerosis (SSc). Serum biomarkers have been suggested as indicators for pulmonary damage with clinical value in the diagnosis and prognosis of SSc-ILD. Objectives To investigate the role of serum biomarkers (Krebs von den Lungen-6 KL-6, IL-18 and IL-18BP) as potential biomarkers reflecting the severity of SSc-ILD as assessed through high-resolution computed tomography (HRCT) and pulmonary function tests (PFT), including forced vital capacity (%FVC) and diffusing capacity of the lung for carbon monoxide (%DLCO). Methods A cross-sectional study including patients with SSc fulfilling the 2013 ACR/EULAR criteria was performed. Patients were classified according to disease duration and pulmonary involvement (presence of ILD). All SSc patients underwent chest HRCT scans and pulmonary function test at baseline. Serum concentration of KL-6, IL8 and IL18BP were determined using sandwich ELISA technique (solid phase sandwich Enzyme Linked-Immunosorbent Assay), with kits from MyBiosource for KL-6 and from Invitrogen for IL18 and IL18BP. A semiquantitative grade of ILD extent was evaluated through HRCT scan (grade 1, 0–20%; grade 2, >20%). Extensive lung disease was defined as >20% of lung involvement on HRCT, and FVC <70% predicted and limited lung involvement as ≤20% of ILD involvement on HRCT, and an FVC ≥70% predicted. Results 74 patients were included, 27% were male. The mean age at diagnosis was 57.5±15 years. The mean time since diagnosis was 7.67±8 years. 28 patients had ILD (38%). 64 % of patients had <20% of ILD extent classified through HRCT scan. SSc-ILD patients had elevated serum KL-6 and IL-18 levels compared to patients without ILD (p=0.003 and p=0.04), and those findings were preserved after adjusting for age and sex (Table 1). Mean erythrocyte sedimentation rate (ESR) was higher in patients with SSc-ILD. A negative correlation between KL-6 levels and %FVC (β=-0.25, p 0.037) and %DLCO (β=-0.28, p 0.02) and between IL-18 levels and %FVC (β=-0.20, p 0.03) and %DLCO (β=-0.14, p 0.04) were found. Linear regression models representing correlation between KL-6 and PFT are represented in the scatter plot in Figure 1. Serum KL-6 and IL-18 levels successfully differentiated grades 1 and 2 (p = 0.028 and p=0.021). Semiquantitative grades of ILD on the HRCT scan were significantly proportional to the KL-6 (p 0.01) and IL-18 (p=0.03). A positive correlation between extensive lung disease and KL-6 (β=0.61, p 0.007) but not with IL-18 was found. Conclusion Serum KL-6 levels and IL-18 were increased in patients with SSc-ILD and showed a positive correlation with ILD severity as measured using a semiquantitative HRCT grading scale and a negative correlation with PFT parameters. KL-6 is positively correlated with extensive lung disease. Serum KL-6 and IL-18 could be a clinically useful biomarker in screening and evaluating SSc-ILD. Reference [1]Lee, J.S., Lee, E.Y., Ha, YJ. et al. Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease. Arthritis Res Ther 21, 58 (2019). https://doi.org/10.1186/s13075-019-1835-9 Acknowledgements: NIL. Disclosure of Interests None Declared.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Background Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with systemic sclerosis (SSc). Serum biomarkers have been suggested as indicators for pulmonary damage with clinical value in the diagnosis and prognosis of SSc-ILD. Objectives To investigate the role of serum biomarkers (Krebs von den Lungen-6 KL-6, IL-18 and IL-18BP) as potential biomarkers reflecting the severity of SSc-ILD as assessed through high-resolution computed tomography (HRCT) and pulmonary function tests (PFT), including forced vital capacity (%FVC) and diffusing capacity of the lung for carbon monoxide (%DLCO). Methods A cross-sectional study including patients with SSc fulfilling the 2013 ACR/EULAR criteria was performed. Patients were classified according to disease duration and pulmonary involvement (presence of ILD). All SSc patients underwent chest HRCT scans and pulmonary function test at baseline. Serum concentration of KL-6, IL8 and IL18BP were determined using sandwich ELISA technique (solid phase sandwich Enzyme Linked-Immunosorbent Assay), with kits from MyBiosource for KL-6 and from Invitrogen for IL18 and IL18BP. A semiquantitative grade of ILD extent was evaluated through HRCT scan (grade 1, 0–20%; grade 2, >20%). Extensive lung disease was defined as >20% of lung involvement on HRCT, and FVC <70% predicted and limited lung involvement as ≤20% of ILD involvement on HRCT, and an FVC ≥70% predicted. Results 74 patients were included, 27% were male. The mean age at diagnosis was 57.5±15 years. The mean time since diagnosis was 7.67±8 years. 28 patients had ILD (38%). 64 % of patients had <20% of ILD extent classified through HRCT scan. SSc-ILD patients had elevated serum KL-6 and IL-18 levels compared to patients without ILD (p=0.003 and p=0.04), and those findings were preserved after adjusting for age and sex (Table 1). Mean erythrocyte sedimentation rate (ESR) was higher in patients with SSc-ILD. A negative correlation between KL-6 levels and %FVC (β=-0.25, p 0.037) and %DLCO (β=-0.28, p 0.02) and between IL-18 levels and %FVC (β=-0.20, p 0.03) and %DLCO (β=-0.14, p 0.04) were found. Linear regression models representing correlation between KL-6 and PFT are represented in the scatter plot in Figure 1. Serum KL-6 and IL-18 levels successfully differentiated grades 1 and 2 (p = 0.028 and p=0.021). Semiquantitative grades of ILD on the HRCT scan were significantly proportional to the KL-6 (p 0.01) and IL-18 (p=0.03). A positive correlation between extensive lung disease and KL-6 (β=0.61, p 0.007) but not with IL-18 was found. Conclusion Serum KL-6 levels and IL-18 were increased in patients with SSc-ILD and showed a positive correlation with ILD severity as measured using a semiquantitative HRCT grading scale and a negative correlation with PFT parameters. KL-6 is positively correlated with extensive lung disease. Serum KL-6 and IL-18 could be a clinically useful biomarker in screening and evaluating SSc-ILD. Reference [1]Lee, J.S., Lee, E.Y., Ha, YJ. et al. Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease. Arthritis Res Ther 21, 58 (2019). https://doi.org/10.1186/s13075-019-1835-9 Acknowledgements: NIL. Disclosure of Interests None Declared.

Key concepts: Medicine, DLCO, Interstitial lung disease, Pulmonary function testing, Vital capacity, Diffusing capacity, Internal medicine, High-resolution computed tomography

Related papers

Back to paper searchBrowse research topicsOriginal source
POS1287 KL6 AND IL-18 LEVELS ARE NEGATIVELY CORRELATED WITH RESPIRATORY FUNCTION TESTS AND ILD EXTENT ASSESSED ON HRCT IN PATIENTS WITH SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE (SSC-ILD) — Research Paper | ScholarLens